Neratinib enhances the efficacy of CDK4/6 inhibitor plus endocrine therapy in HR+/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5pLiushan Chen, Qianjun Chen|Scientific Reports|2024Cited by 2